Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

Tumor necrosis factor-α (TNFα) antagonists have advanced the management of inflammatory bowel diseases patients leading to an improvement of patient's quality of life with the reduction of number of surgeries and hospitalizations. Despite these advances, many patients do not respond to the indu...

Descripción completa

Detalles Bibliográficos
Autores principales: Roda, Giulia, Jharap, Bindia, Neeraj, Narula, Colombel, Jean-Frederic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical/Narrative Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737871/
https://www.ncbi.nlm.nih.gov/pubmed/26741065
http://dx.doi.org/10.1038/ctg.2015.63
_version_ 1782413537376731136
author Roda, Giulia
Jharap, Bindia
Neeraj, Narula
Colombel, Jean-Frederic
author_facet Roda, Giulia
Jharap, Bindia
Neeraj, Narula
Colombel, Jean-Frederic
author_sort Roda, Giulia
collection PubMed
description Tumor necrosis factor-α (TNFα) antagonists have advanced the management of inflammatory bowel diseases patients leading to an improvement of patient's quality of life with the reduction of number of surgeries and hospitalizations. Despite these advances, many patients do not respond to the induction therapy (primary non-response—PNR) or lose response during the treatment (secondary loss of response—LOR). In this paper we will provide an overview of the definition, epidemiology and risk factors for PNR and LOR, as well as discuss the therapeutic options for managing LOR.
format Online
Article
Text
id pubmed-4737871
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-47378712016-02-19 Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management Roda, Giulia Jharap, Bindia Neeraj, Narula Colombel, Jean-Frederic Clin Transl Gastroenterol Clinical/Narrative Review Tumor necrosis factor-α (TNFα) antagonists have advanced the management of inflammatory bowel diseases patients leading to an improvement of patient's quality of life with the reduction of number of surgeries and hospitalizations. Despite these advances, many patients do not respond to the induction therapy (primary non-response—PNR) or lose response during the treatment (secondary loss of response—LOR). In this paper we will provide an overview of the definition, epidemiology and risk factors for PNR and LOR, as well as discuss the therapeutic options for managing LOR. Nature Publishing Group 2016-01 2016-01-07 /pmc/articles/PMC4737871/ /pubmed/26741065 http://dx.doi.org/10.1038/ctg.2015.63 Text en Copyright © 2016 American College of Gastroenterology http://creativecommons.org/licenses/by-nc-nd/4.0/ Clinical and Translational Gastroenterology is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Clinical/Narrative Review
Roda, Giulia
Jharap, Bindia
Neeraj, Narula
Colombel, Jean-Frederic
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
title Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
title_full Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
title_fullStr Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
title_full_unstemmed Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
title_short Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
title_sort loss of response to anti-tnfs: definition, epidemiology, and management
topic Clinical/Narrative Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737871/
https://www.ncbi.nlm.nih.gov/pubmed/26741065
http://dx.doi.org/10.1038/ctg.2015.63
work_keys_str_mv AT rodagiulia lossofresponsetoantitnfsdefinitionepidemiologyandmanagement
AT jharapbindia lossofresponsetoantitnfsdefinitionepidemiologyandmanagement
AT neerajnarula lossofresponsetoantitnfsdefinitionepidemiologyandmanagement
AT colombeljeanfrederic lossofresponsetoantitnfsdefinitionepidemiologyandmanagement

Ejemplares similares